APCS: Serum amyloid P-component
Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on APCS, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
- Antibody 1
| Dezamizumab | Phase 2 | GSK | Antibody | InhibitorSerum amyloid P-component inhibitor | 0 |
| Miridesap | Phase 2 | GSK | Small molecule | Cross-linking agentSerum amyloid P-component cross-linking agent | 0 |
- AL amyloidosis0.37
- Aortic stenosis0.27
- Restless legs syndrome0.26
- Bacterial infectious disease0.21
- Splenic disorder0.21
- Acute tonsillitis0.17
- Pneumonia0.14
- Amyloidosis0.11
- Inherited retinal dystrophy0.10
- Systemic lupus erythematosus0.09
- Autosomal systemic lupus erythematosus type 160.09
- Alzheimer disease0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4929, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P02743, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets